This low float stock was up over 70% on no news this morning

Good day, Trader! Here are our top 4 trade ideas today. These setups look primed! Be the best prepared trader on the Street!  - [Synaptogenix (SNPX)* -]( An undervalued gem by most measures - JPM- 2nd day play, beat on top and bottom line Friday - ACOR - Receives $16.5 million award in AMPYRA arbitration case, up over 55% in pre-market - INPX- Low float Inpixon up over 70% on no news *This is an Issuer-Paid Advertisement, See Disclosure Below  Sponsored By [Synaptogenix (SNPX)-]( Potentially an undervalued gem by most measures Despite the overall market selloff recently, some sectors are still holding up well and outperforming. Biotech is one of those strong sectors. When Biogen (BIIB) announced positive Phase 3 trial results for its Alzheimer’s treatment a few weeks ago, it gapped over 40% and increased its stock value by over $10 billion in 1 day. Here’s what President and Chief Scientific Officer of Snaptogenix Dr. Daniel Alkon had to say about those results  “We continue to welcome the significant commitment that Biogen and Eisai are making towards developing a new treatment option for Alzheimer’s disease (AD). Synaptogenix shares the same commitment to treat AD, although the focus of Synaptogenix resources are toward the actual restoration of function and disease reversal, versus a singular focus on slowing the disease’s rate of clinical decline. Here is a picture of the restorative potential of Bryostatin. Here are before and after images of regenerated synapses in the brain ([source]().   According to FINVIZ, [SNPX]( has a market value of less than $45 million based on yesterday’s close. Given that their cash position at the end of Q2 2022 was over $28.7 million, I believe that currently the market is overlooking the potential of a possibly game-changing biotech in the Alzheimer’s treatment space. Consider for example that its direct competitor SAVA is valued at over $1.5 billion.  Remember: [SNPX]( has Q4 Phase 2 data for its Alzheimer's drug set to be released at any time before the end of the year. This could be a game changer for the company! I have seen many examples where a successful outcome in the FDA process has drastically changed the valuation for a company into the billions. We are all eagerly anticipating SNPX’s results!  [Boardroom Investing]( has conducted an in depth research report into the company, you can access it [here.](  [ Click Here To Find Out More About the Company Working To Reverse the Effects of Alzheimers, A Multi-Billion Market Opportunity](  *This is an Issuer-Paid Advertisement, See Disclosure Below  Don’t Miss Our Alerts Download the[360 App](in the [App Store]( or [Google Play!]( Subscribers receive alerts on trades, webinars and events! Alerts will be sent through email and the [360 App](, which is another amazing tool you should make SURE to put in your toolbox now that you have access to it.  [Follow these instructions]( on how to download and use the app.  Just scan using your phone camera, or [CLICK HERE]( from your smartphone [Here is your direct link to download the 360 Wall Street App in the App Store](  JPM- 2nd day play, beat on top and bottom line Friday The banks were the only sector to finish green on Friday as tech and most of the rest of the market sold off. JPM Morgan (JPM) and a host of other banks that reported beat on the top and bottom line, Bank of America (BAC) also beat earnings estimates this morning and is gapping higher. With the QQQ’s green this morning, this is definitely a sector to watch!  To the downside the $110 level is an area of potential support. It was resistance last week and JPM bounced off that level 3 times for $1 to $2 moves to the upside. The $112 level will be an important pivot. If JPM can hold above it, $113/$113.30 is the next potential target with $115 above that. Below $112, I would look at $110 and if that fails, $109/$108 as potential targets today. [Here is your direct link to the 360 Wall Street Chat Room](  ACOR - Receives $16.5 million award in AMPYRA arbitration case, up over 55% in pre-market ACOR, a micro cap with a market capitalization of $8.51 on Friday’s close according to Finviz received a $16.5 million award this morning and is gapping 55% higher in the pre-market on the news. This is a low priced stock that the day traders will probably be all over today as it has already traded over 4 million shares before the opening bell.  $0.5 will be an important pivot for the stock today. Below that I can see it trade back to $0.4 or lower. Above $0.5 there is resistance in the premarket at $0.55 and $0.569 and a high of $0.63 this a.m. If things really get going the next resistance area above that would be $0.75/$0.789 and then the $1 psychological level. The stock is down over 90% from last year’s levels [Here is your direct link to the 360 Wall Street Chat Room](  INPX- Low float Inpixon up over 70% on no news There was no news in INPX this morning but it was up over 70% higher in the pre-market. The stock had a [1 for 75 reverse split on the 7th of October 22](reducing its outstanding shares from over 100 million to just [2.12 million according to Finviz](. Given that on split adjusted basis, it traded the most volume it has done so in over a year on Friday. There are not many shares available to trade and thus the price of this stock can be moved around more easily by big traders. Perhaps some traders spotted this over the weekend. INPX has already traded over 1 million shares in the pre-market, which is almost double that of Friday and ½ the float. This is one that could get wild today.  Based off after-hours action there is potential support at $6 and $7.30 in INPX. There is resistance at $8 and $9 above that. $10 is also a psychological target and prior resistance. Above that $13, $16 and $18.50 are in play if things get really crazy! INPX closed at $4.78 on Friday, so that could be the target if the buyers walk this a.m [Here is your direct link to the 360 Wall Street Chat Room](  To your success! 62 Calef Hwy #233 Lee, New Hampshire 03861 United States Questions or concerns about our products? Email [Support@360.com](  © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions  FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, neither Sherwood Ventures, LLC (“Sherwood”) nor Ragingbull.com, LLC (“Raging Bull”) can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither Sherwood nor Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at. TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. ISSUER-PAID ADVERTISEMENT. Synaptogenix, Inc. (“SNPX” or the “Company”) has paid or will pay Sherwood $30,000 USD per month for three months (the “Initial Term”) in cash, shares of restricted common stock with a value of $150,000, and warrants valued at issuance of $75,000 for marketing services including communicating to the public about the company through Sherwood’s affiliate Raging Bull, among others. This advertisement is part of those issuer-paid marketing services. The contract with SNPX automatically renews for successive one-month periods following the Initial Term (the “Renewal Term”) unless it is terminated by written notice of either party prior to the end of the previous term. During the Renewal Term, SNPX has agreed to pay Sherwood a monthly fee of $30,000 in cash, shares of restricted stock with a value of $50,000 and warrants valued at $25,000. As a result of this advertisement and other marketing efforts, Sherwood and/or Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, Sherwood and Raging Bull, and any of their respective officers, principals, or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) hold the securities of SNPX and, as permitted by law, may sell those shares during the course of this marketing arrangement or afterwards. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of SNPX, increased trading volume, and possibly an increased share price of the SNPX’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. [Manage your email subscriptions.](